Cumberland Pharmaceuticals Inc (CPIX) 4.30 $CPIX
Cumberland Pharmaceuticals Launches Vaprisol® Promotion
PR Newswire - Wed May 07, 6:00AM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced the launch of its active promotional campaign to support its new Vaprisol® product. Cumberland will promote Vaprisol across the United States through its hospital sales force. A National Sales Meeting was convened this week to officially launch active promotion and other efforts to support the brand. Cumberland acquired Vaprisol from Astellas Pharma US earlier this year and has been distributing the product since.
Cumberland Pharmaceuticals And Gloria Pharmaceuticals Announce Joint Research & Development Investment
PR Newswire - Tue May 06, 6:00AM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) and China's Gloria Pharmaceuticals Co. (SHE: 002437) announced today a joint research & development initiative. Each company has made a $1 million investment in Cumberland Emerging Technologies ("CET"
, which is majority owned by Cumberland and partners with academic research centers to develop promising biopharmaceutical technologies. The new funds will be used to accelerate development of CET's pipeline of new product candidates emerging from Vanderbilt University and other regional research centers.
Cumberland Pharmaceuticals To Announce First Quarter 2014 Financial Results On May 13, 2014
PR Newswire - Tue Apr 29, 4:00PM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2014 financial results after the market closes on Tuesday, May 13, 2014. A conference call and live Internet webcast will be held on Tuesday, May 13, 2014, at 4:30 p.m. Eastern Time to discuss the results.
Caldolor® Pediatric Pain Study Results To Be Presented At The Pediatric Anesthesiology 2014 Conference
PR Newswire - Fri Mar 07, 1:04PM CST
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that data from a recent study evaluating the efficacy and safety of Caldolor® (ibuprofen) Injection will be presented at the Pediatric Anesthesiology 2014 conference in Fort Lauderdale, Florida.
Cumberland Pharmaceuticals Reports 2013 Fourth Quarter And Annual Financial Results
PR Newswire - Tue Mar 04, 3:05PM CST
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and annual 2013 financial results. The Company also recently announced the acquisition of Vaprisol, a marketed critical care product from Astellas Pharma US, Inc.
Cumberland Pharmaceuticals Acquires Vaprisol® from Astellas Pharma US, Inc.
PR Newswire - Mon Mar 03, 7:05AM CST
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) today announced the acquisition of Vaprisol® from Astellas Pharma US, Inc.
Cumberland Pharmaceuticals To Announce 2013 Year-End Financial Results On March 4, 2014
PR Newswire - Thu Feb 27, 12:28PM CST
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release 2013 year-end financial results after the market closes on Tuesday, March 4, 2014. A conference call and live Internet webcast will be held on Tuesday, March 4, 2014, at 4:30 p.m. Eastern Time to discuss the results.
Buffalo Announces LinkStation 200 Series of Easy To Use Network Attached Storage
PR Newswire - Tue Jan 07, 10:51AM CST
CONSUMER ELECTRONICS SHOW (CES) -- Buffalo Americas, a global leader in the design, development and manufacturing of wired and wireless networking and network and direct attached storage solutions, today announced its LinkStation(TM) 200 Series of easy to use network storage devices. Ideal for home users, the new LinkStation 200 Series provides simple network storage and backup and offers an assortment of features, allowing users to store, organize, access and stream media files from any computer, smartphone or tablet. Users can even set up a free personal cloud for access anytime, anywhere, at home or on the go.
Biopharma Grifols Builds In Blood Therapies Worldwide
at Investor's Business Daily - Wed Dec 11, 4:23PM CST
Biopharma plasma firm Grifols isn't letting Spain's financial crisis get it down. International expansion is a key component of the Barcelona-based company's growth strategy. Though that expansion began in the 1990s, its acquisition of North...
Cardiovascular Inflammation Global Clinical Trials Review, H2, 2013 Out Now
M2 - Thu Sep 12, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/87csvr/cardiovascular) has announced the addition of the "Cardiovascular Inflammation Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Cardiovascular Inflammation Global Clinical Trials Review, H2, 2013" provides data on the Cardiovascular Inflammation clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cardiovascular Inflammation. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cardiovascular Inflammation. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Anthera Pharmaceuticals Inc. AstraZeneca PLC Cumberland Pharmaceuticals, Inc. F. Hoffmann-La Roche Ltd. Genentech, Inc. GlaxoSmithKline plc Immunomedics, Inc. Innovaderm Research Inc. Janssen Biotech, Inc. Novartis AG Pluristem Therapeutics Inc. RNL BIO Co., Ltd. Robert Bosch GmbH Sanofi TNO Pharma Teijin Pharma Limited Troikaa Pharmaceuticals Ltd. UMC Utrecht Holding BV For more information visit http://www.researchandmarkets.com/research/87...iovascular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cumberland Pharmaceuticals Reports Second Quarter Financial Results
PR Newswire - Tue Aug 06, 3:05PM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced second quarter 2013 financial results.
Cumberland Pharmaceuticals To Announce Second Quarter 2013 Financial Results On August 6, 2013
PR Newswire - Mon Jul 29, 3:05PM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release its second quarter 2013 results after the market closes on Tuesday, August 6, 2013. A conference call and live Internet webcast will be held on Tuesday, August 6, 2013, at 4:30 p.m. Eastern Time to discuss the results.
Cumberland Pharmaceuticals Reports FDA Approval For Updated Acetadote® Labeling
PR Newswire - Mon Jun 10, 7:05AM CDT
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that the U.S. Food and Drug Administration (FDA) has approved updated labeling for Acetadote (acetylcysteine) Injection. The new labeling revises the product's indication and offers new dosing guidance for specific patient populations. Acetadote is free of EDTA or any other stabilization or chelating agents.
Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
PR Newswire - Wed May 15, 1:59PM CDT
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the UBS Global Healthcare Conference at the Sheraton New York hotel on Monday, May 20, 2013, at 9:30 a.m. Eastern Time.
Cumberland Pharmaceuticals Reports First Quarter Financial Results
PR Newswire - Thu May 02, 3:05PM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2013 financial results.
VOLC, ZIOP, DCT, GSIT, SCOR, CPIX Expected To Be Down After Next Earnings Releases
M2 - Wed May 01, 5:54AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Thursday, May 2nd 2013 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and June earnings reports. Volcano Corp (NASDAQ:VOLC), ZIOPHARM Oncology Inc (NASDAQ:ZIOP), DCT Industrial Trust Inc (NYSE
CT), GSI Technology Inc (NASDAQ:GSIT), COMSCORE, INCORPORATION (NASDAQ:SCOR), Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) are all expected to be Down After their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down After earnings are released Thursday:
Cumberland Pharmaceuticals Has Returned 22.4% Since SmarTrend Recommendation (CPIX)
Comtex SmarTrend(R) - Fri Mar 15, 4:47PM CDT
SmarTrend identified a Downtrend for Cumberland Pharmaceuticals (NASDAQ:CPIX) on May 18th, 2012 at $6.56. In approximately 10 months, Cumberland Pharmaceuticals has returned 22.41% as of today's recent price of $5.09.
WEALTHMAKERS.COM Issues Bearish Research Reports on CAMP, CPIX, FSCI, NUAN, SEM, UVV
M2 - Fri Mar 01, 2:59AM CST
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: CalAmp Corp (NASDAQ:CAMP), Cumberland Pharmaceuticals Inc (NASDAQ:CPIX), Fisher Communications Inc (NASDAQ:FSCI), Nuance Communications Inc (NASDAQ:NUAN), Select Medical Holdings Corp (NYSE:SEM), Universal Corp (NYSE:UVV)
Cumberland Pharmaceuticals Reports 2012 Annual Financial Results
PR Newswire - Thu Feb 28, 3:00PM CST
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and annual 2012 financial results.
NOG, CPIX, MOTR, BODY Expected To Be Down After Next Earnings Releases
M2 - Wed Feb 27, 3:53AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Thursday, February 28th 2013 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and June earnings reports. Nordic Oil and Gas Ltd (AMEX:NOG), Cumberland Pharmaceuticals Inc (NASDAQ:CPIX), Motricity Inc (NASDAQ:MOTR), Body Central Corp (NASDAQ:BODY) are all expected to be Down After their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a l
Cumberland Pharmaceuticals Launches Vaprisol® Promotion
PR Newswire - Wed May 07, 6:00AM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced the launch of its active promotional campaign to support its new Vaprisol® product. Cumberland will promote Vaprisol across the United States through its hospital sales force. A National Sales Meeting was convened this week to officially launch active promotion and other efforts to support the brand. Cumberland acquired Vaprisol from Astellas Pharma US earlier this year and has been distributing the product since.
Cumberland Pharmaceuticals And Gloria Pharmaceuticals Announce Joint Research & Development Investment
PR Newswire - Tue May 06, 6:00AM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) and China's Gloria Pharmaceuticals Co. (SHE: 002437) announced today a joint research & development initiative. Each company has made a $1 million investment in Cumberland Emerging Technologies ("CET"
, which is majority owned by Cumberland and partners with academic research centers to develop promising biopharmaceutical technologies. The new funds will be used to accelerate development of CET's pipeline of new product candidates emerging from Vanderbilt University and other regional research centers. Cumberland Pharmaceuticals To Announce First Quarter 2014 Financial Results On May 13, 2014
PR Newswire - Tue Apr 29, 4:00PM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2014 financial results after the market closes on Tuesday, May 13, 2014. A conference call and live Internet webcast will be held on Tuesday, May 13, 2014, at 4:30 p.m. Eastern Time to discuss the results.
Caldolor® Pediatric Pain Study Results To Be Presented At The Pediatric Anesthesiology 2014 Conference
PR Newswire - Fri Mar 07, 1:04PM CST
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that data from a recent study evaluating the efficacy and safety of Caldolor® (ibuprofen) Injection will be presented at the Pediatric Anesthesiology 2014 conference in Fort Lauderdale, Florida.
Cumberland Pharmaceuticals Reports 2013 Fourth Quarter And Annual Financial Results
PR Newswire - Tue Mar 04, 3:05PM CST
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and annual 2013 financial results. The Company also recently announced the acquisition of Vaprisol, a marketed critical care product from Astellas Pharma US, Inc.
Cumberland Pharmaceuticals Acquires Vaprisol® from Astellas Pharma US, Inc.
PR Newswire - Mon Mar 03, 7:05AM CST
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) today announced the acquisition of Vaprisol® from Astellas Pharma US, Inc.
Cumberland Pharmaceuticals To Announce 2013 Year-End Financial Results On March 4, 2014
PR Newswire - Thu Feb 27, 12:28PM CST
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release 2013 year-end financial results after the market closes on Tuesday, March 4, 2014. A conference call and live Internet webcast will be held on Tuesday, March 4, 2014, at 4:30 p.m. Eastern Time to discuss the results.
Buffalo Announces LinkStation 200 Series of Easy To Use Network Attached Storage
PR Newswire - Tue Jan 07, 10:51AM CST
CONSUMER ELECTRONICS SHOW (CES) -- Buffalo Americas, a global leader in the design, development and manufacturing of wired and wireless networking and network and direct attached storage solutions, today announced its LinkStation(TM) 200 Series of easy to use network storage devices. Ideal for home users, the new LinkStation 200 Series provides simple network storage and backup and offers an assortment of features, allowing users to store, organize, access and stream media files from any computer, smartphone or tablet. Users can even set up a free personal cloud for access anytime, anywhere, at home or on the go.
Biopharma Grifols Builds In Blood Therapies Worldwide
at Investor's Business Daily - Wed Dec 11, 4:23PM CST
Biopharma plasma firm Grifols isn't letting Spain's financial crisis get it down. International expansion is a key component of the Barcelona-based company's growth strategy. Though that expansion began in the 1990s, its acquisition of North...
Cardiovascular Inflammation Global Clinical Trials Review, H2, 2013 Out Now
M2 - Thu Sep 12, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/87csvr/cardiovascular) has announced the addition of the "Cardiovascular Inflammation Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Cardiovascular Inflammation Global Clinical Trials Review, H2, 2013" provides data on the Cardiovascular Inflammation clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cardiovascular Inflammation. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cardiovascular Inflammation. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Anthera Pharmaceuticals Inc. AstraZeneca PLC Cumberland Pharmaceuticals, Inc. F. Hoffmann-La Roche Ltd. Genentech, Inc. GlaxoSmithKline plc Immunomedics, Inc. Innovaderm Research Inc. Janssen Biotech, Inc. Novartis AG Pluristem Therapeutics Inc. RNL BIO Co., Ltd. Robert Bosch GmbH Sanofi TNO Pharma Teijin Pharma Limited Troikaa Pharmaceuticals Ltd. UMC Utrecht Holding BV For more information visit http://www.researchandmarkets.com/research/87...iovascular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cumberland Pharmaceuticals Reports Second Quarter Financial Results
PR Newswire - Tue Aug 06, 3:05PM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced second quarter 2013 financial results.
Cumberland Pharmaceuticals To Announce Second Quarter 2013 Financial Results On August 6, 2013
PR Newswire - Mon Jul 29, 3:05PM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release its second quarter 2013 results after the market closes on Tuesday, August 6, 2013. A conference call and live Internet webcast will be held on Tuesday, August 6, 2013, at 4:30 p.m. Eastern Time to discuss the results.
Cumberland Pharmaceuticals Reports FDA Approval For Updated Acetadote® Labeling
PR Newswire - Mon Jun 10, 7:05AM CDT
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that the U.S. Food and Drug Administration (FDA) has approved updated labeling for Acetadote (acetylcysteine) Injection. The new labeling revises the product's indication and offers new dosing guidance for specific patient populations. Acetadote is free of EDTA or any other stabilization or chelating agents.
Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
PR Newswire - Wed May 15, 1:59PM CDT
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the UBS Global Healthcare Conference at the Sheraton New York hotel on Monday, May 20, 2013, at 9:30 a.m. Eastern Time.
Cumberland Pharmaceuticals Reports First Quarter Financial Results
PR Newswire - Thu May 02, 3:05PM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2013 financial results.
VOLC, ZIOP, DCT, GSIT, SCOR, CPIX Expected To Be Down After Next Earnings Releases
M2 - Wed May 01, 5:54AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Thursday, May 2nd 2013 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and June earnings reports. Volcano Corp (NASDAQ:VOLC), ZIOPHARM Oncology Inc (NASDAQ:ZIOP), DCT Industrial Trust Inc (NYSE
CT), GSI Technology Inc (NASDAQ:GSIT), COMSCORE, INCORPORATION (NASDAQ:SCOR), Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) are all expected to be Down After their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down After earnings are released Thursday: Cumberland Pharmaceuticals Has Returned 22.4% Since SmarTrend Recommendation (CPIX)
Comtex SmarTrend(R) - Fri Mar 15, 4:47PM CDT
SmarTrend identified a Downtrend for Cumberland Pharmaceuticals (NASDAQ:CPIX) on May 18th, 2012 at $6.56. In approximately 10 months, Cumberland Pharmaceuticals has returned 22.41% as of today's recent price of $5.09.
WEALTHMAKERS.COM Issues Bearish Research Reports on CAMP, CPIX, FSCI, NUAN, SEM, UVV
M2 - Fri Mar 01, 2:59AM CST
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: CalAmp Corp (NASDAQ:CAMP), Cumberland Pharmaceuticals Inc (NASDAQ:CPIX), Fisher Communications Inc (NASDAQ:FSCI), Nuance Communications Inc (NASDAQ:NUAN), Select Medical Holdings Corp (NYSE:SEM), Universal Corp (NYSE:UVV)
Cumberland Pharmaceuticals Reports 2012 Annual Financial Results
PR Newswire - Thu Feb 28, 3:00PM CST
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and annual 2012 financial results.
NOG, CPIX, MOTR, BODY Expected To Be Down After Next Earnings Releases
M2 - Wed Feb 27, 3:53AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Thursday, February 28th 2013 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and June earnings reports. Nordic Oil and Gas Ltd (AMEX:NOG), Cumberland Pharmaceuticals Inc (NASDAQ:CPIX), Motricity Inc (NASDAQ:MOTR), Body Central Corp (NASDAQ:BODY) are all expected to be Down After their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a l
